Bibliographic citations
Tello, T., (2023). Efectividad de la Natamicina Tópica al 5% en pacientes con queratitis micótica atendidos en el Instituto Regional de Oftalmología [Tesis, Universidad Privada Antenor Orrego - UPAO]. https://hdl.handle.net/20.500.12759/10612
Tello, T., Efectividad de la Natamicina Tópica al 5% en pacientes con queratitis micótica atendidos en el Instituto Regional de Oftalmología [Tesis]. PE: Universidad Privada Antenor Orrego - UPAO; 2023. https://hdl.handle.net/20.500.12759/10612
@misc{renati/371672,
title = "Efectividad de la Natamicina Tópica al 5% en pacientes con queratitis micótica atendidos en el Instituto Regional de Oftalmología",
author = "Tello Marín, Tania Lisbeth",
publisher = "Universidad Privada Antenor Orrego - UPAO",
year = "2023"
}
To determine if 5% topical natamycin is effective in the treatment of fungal keratitis, in patients treated at the Regional Institute of Ophthalmology-JSU during the period January 2016 to December 2021. Material and methods: This study corresponds observational, retrospective, longitudinal single cohort design. 72 patients with fungal keratitis were included, according to selection criteria, attended at the Regional Institute of Ophthalmology JSU during the period January 2016 to December 2021. Results: The average age obtained was 43 years; the gender that predominated with 79.2% was male. According to the origin, La Libertad obtained the highest number of cases with 62.5%. Treatment with 5% topical natamycin was effective in functional improvement and clinical improvement in 79.2% and 83% respectively. After treatment, 94% of cases did not present an infiltrate, 93% had an absence of hypopyon and a decrease in the size of the epithelial defect <1 mm2 was 90.3% of the cases. The history with the highest incidence was ocular trauma 56.9% Conclusion: 5% topical natamycin is effective in the treatment of fungal keratitis, in patients treated at the Regional Institute of Ophthalmology-JSU during the period January 2016 to December 2021.
This item is licensed under a Creative Commons License